Tatiana A. Grebennikova

Tatiana A. Grebennikova

Auto-generated profile, based on publicly available information

Tatiana A. Grebennikova

ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2017 in Problems of Endocrinology
Verified
Journal Article
Open access
PDF file
GMGalina A. Mel'NIchenko
Galina A. Mel'NIchenko
ZBZhanna Belaya
Zhanna Belaya
LRLyudmila Ya. Rozhinskaya
Lyudmila Ya. Rozhinskaya
NTNatalia V. Toroptsova
Natalia V. Toroptsova
LALyudmila I. Alekseeva
Lyudmila I. Alekseeva
OLOlga Lesnyak
Olga Lesnyak
Screening using the Fracture Risk Assessment Tool (FRAX) is recommended in all postmenopausal woman and mеn over 50 (A1) in order to identify individuals with high probability of fractures. It is recommended to diagnose osteoporosis and start treatment in patients with fragility fracture of large bones of the skeleton and/or high individual probability of major fragility fractures (FRAX) and/or detected decrease in bone mineral density (BMD) up to –2.5 T-score as assessed by DXA in the femoral neck and/or lumbar vertebrae (A1). Patients with back pain, lifetime height loss of 4 cm or height loss of 2 cm since a previous medical examination, those who receive glucocorticoids, patients with long lasting decompensated type 2 diabetes mellitus, or those receiving insulin therapy, as well as patients who were previously diagnosed with fragility fractures at the other sites are advised to underwent standard lateral X-ray imaging of the spine (Th4—L5) in order to verify the presence of compression vertebral fractures (B1). Dual-energy X-ray absorptiometry (DXA) is recommended for individuals whose 10-year probability of major osteoporotic fracture (FRAX) falls within the medium risk group (B1). It is recommended to include the trabecular bone score (TBS) the FRAX algorithm in order to improve the sensitivity of this method (B1). Laboratory testing is recommended for the differential diagnosis with other causes of increased skeletal fragility in all patients with newly diagnosed osteoporosis and when previously prescribed antiosteoporostic treatment was ineffective (B1). Bisphosphonates (BPs), antibodies to receptor activator of nuclear factor kappa-beta ligand (RANKL) (denosumab), or parathyroid hormone analogue (teriparatide) are equally recommended to prevent fragility fractures and increase BMD in patients with osteoporosis (A1). Denosumab is also recommended to prevent BMD loss and fractures in females receiving aromatase inhibitors therapy for breast cancer and males with prostate cancer receiving hormone-deprivation therapy and having no bone metastases (A1). Since teriparatide has the anabolic effect, it is recommended as the first line treatment in patients with severe osteoporosis having history of vertebral fractures, in the individuals with very high risk of fragility fractures, or in the cases when antiresorptive treatment was ineffective (B1). All medications for treatment of osteoporosis are recommended in combination with calcium and vitamin D supplements (A1).

2 December 2015 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
TGT. A. Grebennikova
T. A. Grebennikova
ZBZh. E. Belaya
Zh. E. Belaya
LRL. Ya. Rozhinskaya
L. Ya. Rozhinskaya
GMG. A. Mel'Nichenko
G. A. Mel'Nichenko
IDI. I. Dedov
I. I. Dedov
Обсуждаются перспективы использования эпигенетических механизмов регуляции остеобласто- и остеокластогенеза в ранней диагностике и лечении остеопороза. Особое внимание уделено классу малых некодирующих регуляторных РНК — микроРНК (мкРНК), которые контролируют экспрессию генов на посттранскрипционном уровне, участвуя практически во всех биологических процессах в клетке, включая клеточную дифференцировку и апоптоз. Изучение роли мкРНК в регуляции костного обмена начаты относительно недавно, однако все более очевидно их участие в патогенезе остеопороза. В статье приведен профиль микроРНК, наиболее значимо влияющих на костный метаболизм. Устойчивость мкРНК к разрушению в периферической крови дает возможность рассматривать некоторые специфичные для костной ткани мкРНК в качестве потенциальных диагностических маркеров костного ремоделирования и остеопороза.

28 February 2021 in Osteoporosis and Bone Diseases
Verified
Journal Article
Open access
PDF file
ZBZhanna Belaya
Zhanna Belaya
LRLyudmila Y. Rozhinskaya
Lyudmila Y. Rozhinskaya
ТГТатьяна Алексеевна Гребенникова
Татьяна Алексеевна Гребенникова
JKJohn A. Kanis
John A. Kanis
EPEKATERINA PIGAROVA
EKATERINA PIGAROVA
АПАлексей Владимирович Петряйкин
Алексей Владимирович Петряйкин
A summary of the draft federal clinical guidelines on osteoporosis developed by members of the Russian Association of Endocrinologists, the Russian Association for Osteoporosis, the Association of Rheumatologists of Russia, the Association of Traumatologists and Orthopedists of Russia, the Russian Association for Menopause and the Russian Association of Gerontologists and Geriatrics is presented. The recommendations were developed from the perspective of evidence-based medicine, in accordance with the requirements for compiling clinical recommendations of the Ministry of Health of Russia published in 2019. A significant place is given to screening of primary osteoporosis in adults, differential diagnosis with other metabolic diseases of the skeleton, modern methods of diagnosing osteoporosis, principles of prescribing pathogenetic treatment, features of sequential and combination therapy, disease prevention and rehabilitation. Clinical recommendations will be useful both to general practitioners and physicians, as well as to narrow specialists, primarily endocrinologists, rheumatologists, orthopedic traumatologists, nephrologists, obstetrician-gynecologists and neurologists, since osteoporosis is a multifactorial and multidisciplinary disease.

4 August 2020 in Problems of Endocrinology
Verified
Journal Article
Open access
ZBZhanna Belaya
Zhanna Belaya
OGOlga O. Golounina
Olga O. Golounina
LRLiudmila Y. Rozhinskaya
Liudmila Y. Rozhinskaya
GMGalina A. Melnichenko
Galina A. Melnichenko
MIMichail А. Isakov
Michail А. Isakov
IDIvan I. Dedov
Ivan I. Dedov
BACKGROUND: The registry is the main source of information about patients with acromegaly for assessing the quality of medical care, effectiveness of treatment, determining the compliance of real clinical practice with existing standards and patient management protocols. AIMS: To evaluate epidemiological, demographic and clinical characteristics of acromegaly in Russian Federation and effectiveness of treatment modalities. MATERIALS AND METHODS: The object of the study was the database of the united Russian registry of patients with pituitary tumors with specific analysis of patients with acromegaly only. We analyzed the data of 4114 patients with acromegaly stored on the online system in February 2019. RESULTS: Based on the data 32% of patients had complete clinical and laboratory remission of acromegaly; the percentage of patients with no remission was 68%, among them 22.5% had significant improvements in clinical symptoms and a decrease in growth hormone (GH) and insulin-like growth factor-1 (IGF-1) without IGF-1 normalization. The average age of patients at the onset of the disease was 42.7 years and at diagnosis 45.8 years. The ratio of men to women was 1:2.6. In patients with acromegaly hypopituitarism was registered in 14.7% of cases and among them hypothyroidism (66%) and hypogonadism (52%) were registered more often. Among other complications the leading were diabetes mellitus (15.7%) and acromegalic arthropathy (15%). The proportion of patients receiving neurosurgical treatment increased from 35.7% to 49.6% in 20122019; the portion of patients undergoing radiation therapy decreased significantly from 17.7% in 2012 to 0.8% in 2019. Remission was achieved in 40.47% after neurosurgery and 28.95% after medical treatment as a first line therapy p0.01. The number of patients receiving medical treatment at the time of the study was 1209. Among them 51% of patients treated with long-acting lanreotide and 24% receiving long-acting octreotide achieved remission (p0.0001) CONCLUSIONS: The remission rate of acromegaly remains suboptimal despite increased surgical activity, which corresponds to global trends. Long-acting lanreotide was significantly superior versus long-acting octreotide in the rate of acromegaly remission, which does not correspond with clinical trials.

10 November 2023 in Problems of Endocrinology
Verified
Journal Article
Open access
PDF file
SGS A Gronskaia
S A Gronskaia
ZBZh E Belaya
Zh E Belaya
LRL Ya Rozhinskaya
L Ya Rozhinskaya
GMG A Melnichenko
G A Melnichenko
TDT A Dubovitskaya
T A Dubovitskaya
IDI I Dedov
I I Dedov
Introduction: Tumor-induced osteomalacia is an acquired rare disease manifested by hypophosphatemic osteomalacia due to excessive secretion of fibroblast growth factor 23 (FGF23). FGF 23 is a non-classical hormone secreted by bone tissue (osteocytes) and regulates phosphorus metabolism.The aim of this work is to present clinical experience in the diagnosis, treatment and rehabilitation of patients with tumor-induced osteomalacia.Materials and methods: 40 patients with clinically-confirmed tumor-induced osteomalacia were included in the study, 34 of whom had the tumor localized, 27 underwent surgical treatment and 21 achieved stable remission.Results: The median age was 48 [41; 63] years, 43% were men, the time left from the the onset of the disease was 8 [4; 10] years. Biochemical findings were hypophosphatemia 0.47 [0.4; 0.53] mmol/l, a decrease in the tubular reabsorption phosphate 62 [52; 67]%, and an increase in alkaline phosphatase of 183 [112; 294] units/l. At the time of diagnosis, 100% had multiple pathological fractures, only 10% could move independently, and 77.5% classified the pain as unbearable (8–10 points according to the 10-point pain syndrome scale ). Among the methods used to detect tumors, the most sensitive were scintigraphy with tectrotide with SPECT/CT 71.4% (20/28) and MRI 90% (18/20). In 35% of cases, the tumor was localized in soft tissues and in 65% in bone tissue; The tumor was most often detected in the lower extremities, followed by the head in frequency of localization. 18 patients currently have no remission and they receive conservative treatment (phosphorus and alfacalcidol n=15 and burosumab n=3). In case of achieving remission (n=21), regression of clinical symptoms and restoration of bone and muscle mass was observed. Extensive excision of the tumor without prior biopsy resulted in the best percentage of remission — 87%.Conclusion: Tumor-induced osteomalacia is characterized by severe damage to bone and muscle tissue with the development of multiple fractures, muscle weakness and severe pain syndrome. In laboratory diagnostics, attention should be paid to hypophosphatemia, a decrease in the tubular reabsorption phosphate index and increased alkaline phosphatase. The use of functional diagnostic methods with a labeled somatostatin analogue to the subtype 2 receptor and MRI with contrast enhancement are the most accurate methods of topical diagnostics. In case of localization of the tumor, a wide excision without a preliminary biopsy is recommended.

17 September 2017 in Endocrine Surgery
Verified
Journal Article
Open access
PDF file
TGTatiana A. Grebennikova
Tatiana A. Grebennikova
ZBZhanna Belaya
Zhanna Belaya
GMGalina A. Melnichenko
Galina A. Melnichenko
Гипопаратиреоз характеризуется гипокальциемией при нормальном или низком уровне паратиреоидного гормона (ПТГ). ПТГ регулирует уровень кальция в крови, влияя на реабсорбцию кальция и фосфора в почках, а также витамин D-зависимое всасывание кальция из желудочно-кишечного тракта. Наиболее распространенной причиной гипопаратиреоза является повреждение околощитовидных желез в ходе хирургического вмешательства в области шеи, в основном по поводу заболеваний щитовидной железы. Стандартные методы лечения включают в себя назначение препаратов кальция и витамина D для поддержания уровня кальция на нижней границе референсного интервала с целью предупреждения гиперкальциурии. Однако в ряде случаев компенсация гипокальциемии требует использования высоких доз препаратов кальция и витамина D, что сопровождается выраженным колебанием уровня кальция крови, внескелетной кальцификацией и ухудшением функции почек. В настоящее время наиболее перспективным методом лечения гипопаратиреоза является заместительная терапия рекомбинантным человеческим ПТГ(1-84), который представляет собой полноразмерный ПТГ. ПТГ(1-84) способствует поддержанию стойкой нормокальциемии, улучшая качество жизни пациентов. Однако влияние ПТГ(1-84) на функцию почек, костный обмен и профилактику других осложнений гипопаратиреоза требует дальнейшего изучения.